相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors
Georgina Meneses-Lorente et al.
INVESTIGATIONAL NEW DRUGS (2021)
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy (vol 31, S472, 2020)
S. V. Liu et al.
ANNALS OF ONCOLOGY (2021)
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Bo Mi Ku et al.
INVESTIGATIONAL NEW DRUGS (2020)
Systematic review of neurotrophic tropomyosin-related kinase inhibition as a tumor-agnostic management strategy
Paula Chu et al.
FUTURE ONCOLOGY (2020)
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
David S. Hong et al.
LANCET ONCOLOGY (2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis.
Christian Diego Rolfo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein
Holger Fischer et al.
NEURO-ONCOLOGY (2020)
Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
M. Patel et al.
ANNALS OF ONCOLOGY (2020)
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer
Paula Chu et al.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)
Clinical validity of FoundationOne liquid CDx (F1L CDx) assay as an aid in selecting patients for treatment with entrectinib
R. Dziadziuszko et al.
ANNALS OF ONCOLOGY (2020)
Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline
R. Dziadziuszko et al.
ANNALS OF ONCOLOGY (2020)
Patient-reported outcomes (PROs) from patients (Pts) with NTRK fusion-positive (NTRK-fp) solid tumours receiving entrectinib in the global phase II STARTRK-2 study
A. P. Conley et al.
ANNALS OF ONCOLOGY (2020)
Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
T. John et al.
ANNALS OF ONCOLOGY (2020)
Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
A. Drilon et al.
ANNALS OF ONCOLOGY (2020)
Management of brain metastases according to molecular subtypes
Riccardo Soffietti et al.
NATURE REVIEWS NEUROLOGY (2020)
Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies
Elena Ardini et al.
ESMO OPEN (2020)
HGG-01. ENTRECTINIB IN RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS: UPDATED DATA IN CHILDREN AND ADOLESCENTS
Giles Robinson et al.
NEURO-ONCOLOGY (2020)
MET mediates entrectinib resistance in ROS1 gene fusion positiveNSCLC
Logan Tyler et al.
CANCER RESEARCH (2020)
Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC
D. S. W. Tan et al.
ANNALS OF ONCOLOGY (2020)
Patient reported outcomes (PROs) analysis for patients with ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) receiving entrectinib in the global phase II STARTRK-2 study
F. Barlesi et al.
ANNALS OF ONCOLOGY (2020)
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)
Liling Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Molecular characterization of cancers with NTRK gene fusions
Zoran Gatalica et al.
MODERN PATHOLOGY (2019)
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Emiliano Cocco et al.
NATURE MEDICINE (2019)
LBA28Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2
R C Doebele et al.
ANNALS OF ONCOLOGY (2019)
Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients
R. Doebele et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Larotrectinib for the treatment of TRK fusion solid tumors
Theodore W. Laetsch et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2019)
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia
Kristen M. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
Tejas Patil et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
Dazhi Liu et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion
Anna F. Farago et al.
JCO PRECISION ONCOLOGY (2018)
P14.19 Preclinical and clinical efficacy of entrectinib in primary and metastatic brain tumors harboring NTRK, ROS1, or ALK gene fusions
S. Rangaraju et al.
NEURO-ONCOLOGY (2017)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
Entrectinib is effective against the gatekeeper and other emerging resistance mutations in NTRK-, ROS1-and ALK- rearranged cancers
Ge Wei et al.
CANCER RESEARCH (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
Elena Ardini et al.
MOLECULAR CANCER THERAPEUTICS (2016)
New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Juliane M. Juergensmeier et al.
CLINICAL CANCER RESEARCH (2014)
Crizotinib: A Review of Its Use in the Treatment of Anaplastic Lymphoma Kinase-Positive, Advanced Non-Small Cell Lung Cancer
James E. Frampton
DRUGS (2013)
分享论文
